Novartis AG (NVS)

84.45
0.60 0.71
NYSE : Health Technology
Prev Close 85.05
Open 84.24
Day Low/High 83.25 / 84.51
52 Wk Low/High 69.18 / 99.84
Volume 1.83M
Avg Volume 2.86M
Exchange NYSE
Shares Outstanding 2.47B
Market Cap 209.77B
EPS 3.10
P/E Ratio 26.33
Div & Yield 2.01 (2.36%)
Amazon, Novartis and Netflix - This is What You Need to Know on Tuesday

Amazon, Novartis and Netflix - This is What You Need to Know on Tuesday

European markets opened flat as investors await the European Central Bank meeting

European Stocks Euphoria Is Running High ... Maybe Too High

European Stocks Euphoria Is Running High ... Maybe Too High

European stock markets are priced almost to perfection ahead of an earnings deluge.

Why I'm Positive on Novartis

Why I'm Positive on Novartis

Here's where to buy NVS.

Surveying the NASH Drug Landscape

Surveying the NASH Drug Landscape

Biotech investors should keep a close eye on the progress in this huge potential market.

Drugmakers Suffer After Trump Tweet

Drugmakers Suffer After Trump Tweet

Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Novartis Shows the World a Take of 2 Charts

Novartis Shows the World a Take of 2 Charts

Novartis has seen some very aggressive buying the past five months -- time to join in.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Now That Dow Has Hit 20,000, GM and Nike Are Hot Stocks

Now That Dow Has Hit 20,000, GM and Nike Are Hot Stocks

Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.

Wake Up Wall Street: Positive Earnings Drive Early Trading Higher

Wake Up Wall Street: Positive Earnings Drive Early Trading Higher

Reports from DuPont and Alibaba looked promising for the markets on Wednesday.

News Out of Europe: Intesa Confirms Potential Bid for Generali

News Out of Europe: Intesa Confirms Potential Bid for Generali

News of Intesa's potential takeover bid extended Generali's three-day gains to 15%.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Prepare for Biotech Action Aplenty Today

As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.

Stocks Gain Steam as Oil Rises; Tyson Foods Shares Sink on Earnings

Stocks Gain Steam as Oil Rises; Tyson Foods Shares Sink on Earnings

U.S. stocks rose early Monday as investors parsed comments from oil officials in Iran and Iraq, hinting at a production cut at next week's OPEC meeting.

Novartis In Talks to Buy Generic Drug Maker

Novartis In Talks to Buy Generic Drug Maker

Novartis is entering into talks to purchase Amneal Pharmaceuticals in a deal that could value the company at $8 billion.

Cramer: With the Election Coming, Valeant's Problem Is Increasing

Cramer: With the Election Coming, Valeant's Problem Is Increasing

We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.

Novartis Shares Slip Tuesday on Falling Profit

Novartis Shares Slip Tuesday on Falling Profit

Shares of the global healthcare company, Novartis, are down after it saw its profits fall in the second quarter.

X(encor) Marks the Spot For Potential Gains

X(encor) Marks the Spot For Potential Gains

You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.

Endo Could Be the Next Activist Target in Generics

Endo Could Be the Next Activist Target in Generics

Problems with mesh products and high leverage might scare away a potential buyer. 

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.

Novartis downgraded at Leerink

Valeant Looks Like a Choirboy Next to Mallinckrodt, Says Andrew Left

Valeant Looks Like a Choirboy Next to Mallinckrodt, Says Andrew Left

Valeant may have troubles, but Mallinckrodt is the poster child of price gouging.

3 Pharma Stocks to Heal Your Portfolio

Dividend yield is the determining factor in this strategy.

U.S. Futures Down as Oil Erases Gains; Fed Statement Expected Today

U.S. Futures Down as Oil Erases Gains; Fed Statement Expected Today

U.S. futures are down ahead of the final day of the Fed's 2-day policy meeting on Wednesday. 

As the World Economic Forum Starts in Davos, Watch These 3 Swiss Stocks

The WEF host country has a lot to offer to investors.

Friday Small-Cap Focus: Xoma

Friday Small-Cap Focus: Xoma

Small biotech plunged in July, but has stabilized on two key deals.